Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01840345 · ClinicalTrials.gov registry record · Phase 2
The Role of N-acetyl-l-cysteine (NAC) as an Adjuvant to Opioid Treatment in Patients With Chronic Neuropathic Pain
A Phase 2 study of Neuropathic Pain, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
- 1
- Study location
NCT01840345 is a Phase 2 study of Neuropathic Pain that has completed, run by Virginia Commonwealth University. The registered enrollment target is 11 participants, below the 101-participant average among 35 other Neuropathic Pain trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01840345, a Phase 2 study of Neuropathic Pain, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will test whether treatment with N-acetyl-L-cysteine (NAC) is safe and decreases pain in patients with chronic neuropathic pain. The investigators hypothesize that NAC will be a useful adjunct to opioid treatment in chronic neuropathic pain.
Conditions Studied
Interventions
- DRUG N-acetyl-l-cysteine
Study Locations (1)
Virginia
- Virginia Commonwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2014-01 |
| Est. Completion | 2017-04-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01840345
The ClinicalTrials.gov registry entry for NCT01840345 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 101-participant average among 35 other Neuropathic Pain trials with a reported enrollment target (89% lower). The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neuropathic Pain appearing as the primary indexed condition, and to 1 intervention - of which N-acetyl-l-cysteine is the first listed.
NCT01840345 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT01840345 about?
NCT01840345 is a clinical study titled "The Role of N-acetyl-l-cysteine (NAC) as an Adjuvant to Opioid Treatment in Patients With Chronic Neuropathic Pain". This study will test whether treatment with N-acetyl-L-cysteine (NAC) is safe and decreases pain in patients with chronic neuropathic pain. The investigators hypothesize that NAC will be a useful adjunct to opioid treatment in chronic neuropathic pain.
What is the current status of trial NCT01840345?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2014-01. Estimated completion is 2017-04-01.
What conditions does trial NCT01840345 study?
This clinical trial studies the following conditions: Neuropathic Pain.
What interventions are being tested in trial NCT01840345?
The interventions under investigation include: N-acetyl-l-cysteine (DRUG).
Who is sponsoring clinical trial NCT01840345?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01840345 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuropathic Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Vitamin D Supplementation on Reported Rates of Taxane-Induced Neuropathy
RECRUITING · Phase 2
-
Proof of Concept Trial of Cannabis Derivatives in Neuropathic Pain
RECRUITING · Phase 2
-
Ginger Root Extract for Sciatic Pain Individuals
RECRUITING · Phase 2
-
Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy
ACTIVE NOT RECRUITING · Phase 2
-
Therapeutic Interventions For Pain Induced By Vincristine Treatment For Childhood Acute Lymphoblastic Leukemia (ALL)
COMPLETED · Phase 2
-
BMS-741672 for Diabetic Neuropathic Pain
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.